A Specialty Biotech ETF Strengthens on Optimism Over CRISPR Advancements | Page 2 of 2 | ETF Trends

Editas and Allergan plan to enroll 10 to 20 patients in the second half of 2019 to test EDIT-101 for treating Leber Congenital Amaurosis type 10, the leading cause of childhood blindness. Edit-101 would be the first-ever in vivo, or editing inside the body, CRISPR medication administered to patients.

CRISPR could enable cheap and rapid “write” capabilities to correct genetic defects.

Looking ahead, CRISPR-based innovations to accelerate given the technology’s ease of use, cost-efficacy, growing body of research surrounding its safety and AI-powered CRISPR nuclease selection tools. CRISPR could also be utilized to address some of the most prominent healthcare problems, which opens up a significant investment opportunity in monogenic diseases.

For more information on the biotech segment, visit our biotechnology category.